Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: AMRN stock price vs AVY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AVY's multiple
Needs AVY P/S.
Implied fair value · at AMRN's multiple
Needs AMRN P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMRN FY 2025 (ended Dec 31, 2025) · AVY FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
AMARIN CORP PLC\UK · implied price per share
Bear
-$0.42
Base
-$0.49
Bull
-$0.56
AVERY DENNISON CORPORATION · implied price per share
Bear
$73.33
Base
$86.27
Bull
$99.21
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.22x
1.66x
Net debt / EBITDA
Leverage against operating earnings
6.57x
2.39x
Cash and equivalents
Liquid reserves on the balance sheet
$302.59M
$202.80M
Total debt
Interest-bearing obligations outstanding
$99.83M
$3.72B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LIGAND PHARMACEUTICALS INC
AMRN vs LGND
Harmony Biosciences Holdings, Inc.
AMRN vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
AMRN vs SUPN
Viatris Inc
AMRN vs VTRS
Organon & Co.
AMRN vs OGN
INCYTE CORP
AMRN vs INCY
3M CO
AMRN vs MMM
EASTMAN CHEMICAL CO
AMRN vs EMN
ILLINOIS TOOL WORKS INC
AMRN vs ITW
RPM INTERNATIONAL INC/DE/
AMRN vs RPM
BRADY CORP
AMRN vs BRC
METTLER TOLEDO INTERNATIONAL INC/
AMRN vs MTD
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe AMRN can re-rate meaningfully above its current 32.2x sales multiple despite negative margins and declining revenue, then hold or buy only on a highly speculative basis because AVY comparison points to substantial overvaluation versus AVY.
AMRN trades at a severe premium to AVY-implied valuation, with downside of 95.5% to the implied $0.74 price. The gap is driven by AMRN’s much higher sales multiple and weaker earnings power versus AVY’s far more established profitability profile.
Supporting Metrics
Live quote
